A Randomized, Double-blind, Placebo-Controlled Trial To Evaluate The Safety And Immunogenicity Of LFnp24B.C, a Therapeutic HIV Vaccine,in HIV-infected Chinese Patients Receiving Stable ART treatment

Trial Profile

A Randomized, Double-blind, Placebo-Controlled Trial To Evaluate The Safety And Immunogenicity Of LFnp24B.C, a Therapeutic HIV Vaccine,in HIV-infected Chinese Patients Receiving Stable ART treatment

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2016

At a glance

  • Drugs LFn-p24-B-C (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Haikou VTI Biological Institute
  • Most Recent Events

    • 19 Apr 2016 Status changed from not yet recruiting to completed according to the Chinese Clinical Trial Register record.
    • 04 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top